RxDoctor Payments Data

Corey Henderson

Primary Care · Sebring, FLNPI 1568834224

Payments from drug & device makers

$2,257in general payments, 2019–2025

Across 126 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$443
  • AbbVie$311
  • Madrigal Pharmaceuticals$263
  • Aimmune Therapeutics, Inc.$133
  • Lilly USA, LLC$133
  • Regeneron Healthcare Solutions, Inc.$129
  • plus $844 from 18 others

What the payments were for

  • Food & beverage$2,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,257 in reported general payments places this provider in the 85th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$78,412
Medicare patients
488
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase50$237,864
Dupixent PenDupilumab13$101,850
Famotidine437$8,701
Pantoprazole Sodium253$3,335
Mesalamine16$2,599
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl79$1,318
Omeprazole42$882
Sucralfate29$826
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$721
Dicyclomine Hcl43$678
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl40$617
Lansoprazole14$573
Esomeprazole Magnesium13$489
Metronidazole29$436
Ondansetron OdtOndansetron20$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$311$237,86450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 725 primary care providers in Florida.

Other primary care in Sebring

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →